Rosuvastatin Therapy in Patients with Non‑Alcoholic Fatty Liver Disease (NAFLD)

Safety and Indications

The American Association of Clinical Endocrinology (AACE) 2022 guideline states that statins, including rosuvastatin, are safe for patients with NAFLD or NASH but should not be used in decompensated cirrhosis (Child‑Pugh Class C) – a strong recommendation. 1
The American Heart Association/American College of Cardiology (AHA/ACC) 2019 guideline recommends that, in adults with increased atherosclerotic cardiovascular disease (ASCVD) risk and chronic stable liver disease (including NAFLD), it is reasonable to initiate statin therapy after obtaining baseline laboratory measurements and establishing a monitoring plan. 3
The joint American Gastroenterological Association / American Association for the Study of Liver Diseases / American College of Gastroenterology (AGA/AASLD/ACG) 2012 guideline confirms that statins can be used to treat dyslipidemia in NAFLD/NASH patients, with strong evidence that these patients are not at higher risk for serious drug‑induced liver injury. 5

The Canadian Working Group (2013) reported that rosuvastatin 5 mg daily in NAFLD patients produced reductions in hepatic fibrosis and steatosis. 7

Obtain a hepatic panel (AST, ALT, total bilirubin, alkaline phosphatase) before starting rosuvastatin – AHA/ACC 2019 guideline. 3
Obtain a lipid panel before initiation – AACE 2022 guideline. 1
Measure creatine kinase only if the patient reports muscle symptoms – AHA/ACC 2019 guideline. 3

Routine serial monitoring of liver enzymes during chronic rosuvastatin therapy is not recommended, as it does not effectively detect or prevent serious liver injury – Canadian Working Group 2013. 7
Liver enzymes should be checked only if clinical signs or symptoms suggest hepatotoxicity – AHA/ACC 2019 guideline. 3

For patients at high cardiovascular risk, use moderate‑to‑high intensity rosuvastatin (10–20 mg daily) – AACE 2022 guideline. 1
For very high or extreme cardiovascular risk, consider rosuvastatin 20–40 mg daily – AACE 2022 guideline. 1
In statin‑intolerant individuals, a lower dose (5 mg daily) or intermittent dosing (2–3 times per week) is effective and well‑tolerated – Canadian Journal of Cardiology 2013. 9

Decompensated cirrhosis (Child‑Pugh Class C) is a contraindication to rosuvastatin; compensated liver disease (including NAFLD/NASH with fibrosis) is not a contraindication – AACE 2022 and AGA/AASLD/ACG 2012 guidelines. 1

Do not withhold statins solely because of elevated liver enzymes in NAFLD patients, as this deprives them of essential cardiovascular protection – AGA/AASLD/ACG 2012 guideline. 5
Do not perform routine liver‑enzyme monitoring in the absence of symptoms – AHA/ACC 2019 and Canadian Working Group 2013 guidelines. 3
Do not confuse compensated NAFLD/NASH with decompensated cirrhosis; only the latter contraindicates rosuvastatin – AACE 2022 guideline. 1